Monopar Cash vs Cash And Short Term Investments Analysis

MNPR Stock  USD 24.80  0.54  2.13%   
Monopar Therapeutics financial indicator trend analysis is infinitely more than just investigating Monopar Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Monopar Therapeutics is a good investment. Please check the relationship between Monopar Therapeutics Cash and its Cash And Short Term Investments accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Monopar Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
To learn how to invest in Monopar Stock, please use our How to Invest in Monopar Therapeutics guide.

Cash vs Cash And Short Term Investments

JavaScript chart by amCharts 3.21.152014201620182020202220242M4M6M8M10M12M14M16M18M 4M6M8M10M12M14M16M18M
JavaScript chart by amCharts 3.21.15Cashtotal: 100.1MCash And Short Term Investmentstotal: 107M

Cash vs Cash And Short Term Investments Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Monopar Therapeutics Cash account and Cash And Short Term Investments. At this time, the significance of the direction appears to have almost identical trend.
CashCash And Short Term InvestmentsDiversified AwayCashCash And Short Term InvestmentsDiversified Away100%
The correlation between Monopar Therapeutics' Cash and Cash And Short Term Investments is 0.98. Overlapping area represents the amount of variation of Cash that can explain the historical movement of Cash And Short Term Investments in the same time period over historical financial statements of Monopar Therapeutics, assuming nothing else is changed. The correlation between historical values of Monopar Therapeutics' Cash and Cash And Short Term Investments is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash of Monopar Therapeutics are associated (or correlated) with its Cash And Short Term Investments. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash And Short Term Investments has no effect on the direction of Cash i.e., Monopar Therapeutics' Cash and Cash And Short Term Investments go up and down completely randomly.

Correlation Coefficient

0.98
Relationship DirectionPositive 
Relationship StrengthVery Strong

Cash

Cash refers to the most liquid asset of Monopar Therapeutics, which is listed under current asset account on Monopar Therapeutics balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Monopar Therapeutics customers. The amounts must be unrestricted with restricted cash listed in a different Monopar Therapeutics account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.

Cash And Short Term Investments

Short Term Investments is an account in the current assets section of Monopar Therapeutics balance sheet. This account contains Monopar Therapeutics investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Monopar Therapeutics fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.
Most indicators from Monopar Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Monopar Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Monopar Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
To learn how to invest in Monopar Stock, please use our How to Invest in Monopar Therapeutics guide.As of 12/27/2024, Selling General Administrative is likely to drop to about 2.2 M. In addition to that, Tax Provision is likely to drop to about (67.7 K)
 2021 2022 2023 2024 (projected)
Total Operating Expenses9.1M10.5M8.8M7.5M
Research Development6.5M7.6M5.6M5.3M

Monopar Therapeutics fundamental ratios Correlations

0.690.990.82-0.720.690.98-0.790.681.00.1-0.97-0.78-0.781.00.460.860.330.840.660.610.690.610.610.05-0.14
0.690.590.88-0.861.00.56-0.791.00.70.33-0.55-0.75-0.770.70.80.830.10.890.820.160.240.860.850.36-0.27
0.990.590.76-0.660.590.99-0.750.590.990.06-0.98-0.74-0.740.990.370.810.350.780.590.650.720.540.530.0-0.11
0.820.880.76-0.910.880.78-0.860.880.830.42-0.78-0.84-0.840.830.820.980.210.980.930.270.360.90.890.49-0.3
-0.72-0.86-0.66-0.91-0.86-0.670.9-0.86-0.74-0.670.620.880.89-0.75-0.89-0.91-0.27-0.96-0.910.03-0.07-0.94-0.94-0.650.63
0.691.00.590.88-0.860.56-0.791.00.70.33-0.55-0.75-0.770.70.80.830.10.890.820.160.240.860.850.36-0.27
0.980.560.990.78-0.670.56-0.770.560.980.12-0.99-0.77-0.760.980.410.830.360.790.640.640.710.570.570.09-0.15
-0.79-0.79-0.75-0.860.9-0.79-0.77-0.79-0.81-0.460.741.01.0-0.82-0.71-0.91-0.43-0.92-0.82-0.15-0.26-0.81-0.81-0.430.43
0.681.00.590.88-0.861.00.56-0.790.70.33-0.55-0.75-0.770.70.790.830.10.890.820.160.240.850.850.35-0.27
1.00.70.990.83-0.740.70.98-0.810.70.12-0.97-0.81-0.81.00.470.870.340.850.670.60.670.630.630.07-0.15
0.10.330.060.42-0.670.330.12-0.460.330.12-0.04-0.45-0.450.150.760.40.010.480.63-0.54-0.480.70.720.95-0.95
-0.97-0.55-0.98-0.780.62-0.55-0.990.74-0.55-0.97-0.040.740.73-0.96-0.38-0.82-0.35-0.78-0.62-0.69-0.76-0.54-0.53-0.030.04
-0.78-0.75-0.74-0.840.88-0.75-0.771.0-0.75-0.81-0.450.741.0-0.81-0.68-0.9-0.48-0.9-0.8-0.14-0.25-0.78-0.78-0.430.42
-0.78-0.77-0.74-0.840.89-0.77-0.761.0-0.77-0.8-0.450.731.0-0.81-0.69-0.9-0.46-0.91-0.8-0.14-0.24-0.79-0.79-0.430.42
1.00.70.990.83-0.750.70.98-0.820.71.00.15-0.96-0.81-0.810.480.870.320.850.680.580.660.640.640.09-0.18
0.460.80.370.82-0.890.80.41-0.710.790.470.76-0.38-0.68-0.690.480.740.070.830.91-0.13-0.060.970.970.81-0.63
0.860.830.810.98-0.910.830.83-0.910.830.870.4-0.82-0.9-0.90.870.740.330.980.880.250.350.840.830.45-0.31
0.330.10.350.21-0.270.10.36-0.430.10.340.01-0.35-0.48-0.460.320.070.330.310.02-0.010.050.050.05-0.01-0.02
0.840.890.780.98-0.960.890.79-0.920.890.850.48-0.78-0.9-0.910.850.830.980.310.910.20.30.910.90.5-0.4
0.660.820.590.93-0.910.820.64-0.820.820.670.63-0.62-0.8-0.80.680.910.880.020.910.120.210.980.970.7-0.5
0.610.160.650.270.030.160.64-0.150.160.6-0.54-0.69-0.14-0.140.58-0.130.25-0.010.20.120.990.020.0-0.520.52
0.690.240.720.36-0.070.240.71-0.260.240.67-0.48-0.76-0.25-0.240.66-0.060.350.050.30.210.990.110.09-0.460.46
0.610.860.540.9-0.940.860.57-0.810.850.630.7-0.54-0.78-0.790.640.970.840.050.910.980.020.111.00.74-0.59
0.610.850.530.89-0.940.850.57-0.810.850.630.72-0.53-0.78-0.790.640.970.830.050.90.970.00.091.00.75-0.63
0.050.360.00.49-0.650.360.09-0.430.350.070.95-0.03-0.43-0.430.090.810.45-0.010.50.7-0.52-0.460.740.75-0.8
-0.14-0.27-0.11-0.30.63-0.27-0.150.43-0.27-0.15-0.950.040.420.42-0.18-0.63-0.31-0.02-0.4-0.50.520.46-0.59-0.63-0.8
Click cells to compare fundamentals

Monopar Therapeutics Account Relationship Matchups

Monopar Therapeutics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets13.4M16.9M20.5M13.2M7.3M11.5M
Total Current Liabilities724.2K1.2M1.6M3.1M1.8M1.1M
Total Stockholder Equity12.6M15.7M18.9M10.1M5.6M10.4M
Net Tangible Assets6.9M12.6M15.7M18.9M21.8M10.9M
Retained Earnings(25.9M)(32.2M)(41.3M)(51.8M)(60.2M)(57.2M)
Accounts Payable724.2K1.2M1.6M3.1M1.8M1.1M
Cash13.2M16.7M20.3M8.2M7.3M10.5M
Total Liab724.2K1.2M1.6M3.1M1.8M1.1M
Total Current Assets13.2M16.8M20.5M13.2M7.3M11.2M
Other Current Liab724.2K1.2M1.6M(48.6K)1.8B1.8B
Net Debt(13.2M)(16.7M)(20.3M)(8.2M)(7.3M)(7.6M)
Non Current Assets Total0.0122.4K68.9K61.2K12.6K12.0K
Cash And Short Term Investments13.2M16.7M20.3M13.1M7.3M12.2M
Common Stock Shares Outstanding10.6M11.0M12.5M12.7M14.5M12.7M
Liabilities And Stockholders Equity13.4M16.9M20.5M13.2M7.3M12.6M
Capital Surpluse28.0M28.6M38.5M47.9M55.1M32.5M
Other Current Assets5.4K62.7K217.7K46.0K66.4K99.5K
Other Stockholder Equity38.5M47.9M60.2M61.9M65.8M46.1M
Net Invested Capital12.6M15.7M18.9M10.1M5.6M5.3M
Net Working Capital12.5M15.6M18.9M10.0M5.6M5.3M
Common Stock10.6K11.5K12.6K12.9K14.9K12.7K
Accumulated Other Comprehensive Income(11.0K)(7.9K)(3.2K)8.9K(14.1K)(13.4K)
Capital Stock10.6K11.5K12.6K12.9K14.9K13.2K

Pair Trading with Monopar Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Monopar Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Monopar Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Monopar Stock

  0.61DMAC DiaMedica TherapeuticsPairCorr

Moving against Monopar Stock

  0.84DTIL Precision BioSciencesPairCorr
  0.82ME 23Andme HoldingPairCorr
  0.79VALN Valneva SE ADRPairCorr
  0.77VINC Vincerx PharmaPairCorr
  0.75DOMH Dominari HoldingsPairCorr
The ability to find closely correlated positions to Monopar Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Monopar Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Monopar Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Monopar Therapeutics to buy it.
The correlation of Monopar Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Monopar Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Monopar Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Monopar Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Monopar Stock Analysis

When running Monopar Therapeutics' price analysis, check to measure Monopar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Monopar Therapeutics is operating at the current time. Most of Monopar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Monopar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Monopar Therapeutics' price. Additionally, you may evaluate how the addition of Monopar Therapeutics to your portfolios can decrease your overall portfolio volatility.
News Freq…Investor S…